Genetico Center (CGRM, MOEX: GECO) has published an analytical review of the embryo genetic testing market.
According to the ICMART global report, Russia is among the top 5 countries in the world in terms of the total number of assisted reproductive technology (ART) procedures performed and ranks first in Europe.
Preimplantation genetic testing (PGT) means genetic screening of embryos in the IVF protocol. Embryos are tested for chromosomal abnormalities or monogenic genetic diseases so that the mother to be can receive an embryo that has not inherited the disease and give birth to a healthy child.
The global penetration of PGT (the share of ART cycles performed using PGT) was 3.8% in 2019. According to a report by the Mordor Intelligence research agency, the average annual growth rate of the entire PGT market until 2029 will be 10.5%.
Genetico began implementing PGT into healthcare practice in 2012. Now every 8th IVF cycle in Russia is done with PGT. Genetico’s laboratory is the largest laboratory in Russia in terms of the number of patients.
The PGT market in Russia in 2023 was estimated at approximately RUB 1,758 million (USD 19.5 million). By 2028, the market volume could reach RUB 2,775 million (USD 30 million). In 2022, the PTG penetration rate was 12.2%. By comparison, the highest penetration rate of 32% was observed in the United States in 2017, indicating a great growth potential.
According to international research, the use of PGT increases the pregnancy rate from 31.92% (IVF without PGT) to 74% in the case of IVF with PGT. This is due to the fact that the physician does not transfer embryos that will not develop into a normal pregnancy. With PGT, the patient gets pregnant after 1 or 2 IVF cycles instead of 3 or 4. If PGT is included in compulsory medical insurance, budget expenditures on ineffective IVF cycles (those that do not result in pregnancy) could be reduced by 48%.
According to the Russian Association of Human Reproduction, over the past 7 to 10 years there has been an increase in number of both IVF cycles and IVF cycles with PGT in Russia. The number of IVF cycles using PGT in Russia increased by 25% (21,010) in 2022 compared to 2021.
Figures from other countries:
In the US, PGT penetration was about 23% in 2023. The compound annual growth rate (CAGR) in the US is currently estimated at 5%, meaning that the US PGT market could grow to USD 151.7 million by 2028.
In China, the PGT penetration rate was estimated at 3.8% at the end of 2023. However, the PGT penetration level may reach 10.8% by 2028. China’s PGT market can be estimated at approximately USD 544 million by 2028.
In the UK, the penetration rate was 2% between 2014 and 2016. The market volume was over £1.9 million (USD 2.4 million) in 2023 and is expected to reach £2.8 million (USD 3.6 million) by 2028, with an average CAGR of 6.7%.